Werewolf Price To Sales Ratio vs Ev To Operating Cash Flow Analysis
| HOWL Stock | USD 1.90 0.12 6.74% |
Werewolf Therapeutics financial indicator trend analysis is more than just analyzing Werewolf Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Werewolf Therapeutics is a good investment. Please check the relationship between Werewolf Therapeutics Price To Sales Ratio and its Ev To Operating Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
Price To Sales Ratio vs Ev To Operating Cash Flow
Price To Sales Ratio vs Ev To Operating Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Werewolf Therapeutics Price To Sales Ratio account and Ev To Operating Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Werewolf Therapeutics' Price To Sales Ratio and Ev To Operating Cash Flow is 0.49. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Ev To Operating Cash Flow in the same time period over historical financial statements of Werewolf Therapeutics, assuming nothing else is changed. The correlation between historical values of Werewolf Therapeutics' Price To Sales Ratio and Ev To Operating Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Werewolf Therapeutics are associated (or correlated) with its Ev To Operating Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Operating Cash Flow has no effect on the direction of Price To Sales Ratio i.e., Werewolf Therapeutics' Price To Sales Ratio and Ev To Operating Cash Flow go up and down completely randomly.
Correlation Coefficient | 0.49 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Werewolf Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Werewolf Therapeutics sales, a figure that is much harder to manipulate than other Werewolf Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most indicators from Werewolf Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Werewolf Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.Sales General And Administrative To Revenue is expected to rise to 1.14 this year, although the value of Selling General Administrative will most likely fall to about 13.5 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 216K | 1.1M | 3.1M | 3.3M | Depreciation And Amortization | 216K | 1.1M | 1.8M | 951.3K |
Werewolf Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Werewolf Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.